Skip to content
Shuttingdown

Avidity Biosciences, Inc.

Pharmaceutical Preparations · SAN DIEGO · CA

Distress signal

Moderate confidence (50%)

Updated Oct 19, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Avidity Biosciences, Inc. deregistered its securities (Mar 9, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Avidity Biosciences, Inc. deregistered its securities

    Mar 9, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 d40653d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as specified in its charter) 3020 Callan Road San Diego, California 92121 (858) 401-7900 (Address, including zip code, and telephone number, including area code, of registra…”

  2. Avidity Biosciences, Inc. was delisted from its exchange

    Feb 27, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001599901 Avidity Biosciences, Inc. 001-39321 3020 Callan Rd., San Diego CA CALIFORNIA 92121 858-401-7900 Common Stock 17 CFR 240.12d2-2(a)(2) Tara Petta Director 2026-02-27”

  3. Avidity Biosciences, Inc. received a delisting notice from its exchange

    Feb 26, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note are incorporated herein by reference. On February 27, 2026, the Company (i) notified the Nasdaq Global Select Market ( Nasdaq ) of the consummation of the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) maintain the halt on trading of Company Common Stock, which was effective at 8:00 p.m. East…”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
SEC CIK
0001599901
Website
—
LinkedIn
—
Headquarters
SAN DIEGO, CA
Also known as
Avidity Biosciences LLC, Avidity NanoMedicines LLC
Legal entities
Avidity Biosciences, Inc.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Avidity Biosciences, Inc. — Pharmaceutical Preparations (SIC 2834) — SAN DIEGO, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 d40653d1512g.htm 15-12G 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39321 Avidity Biosciences, Inc. (Exact name of registrant as specified in its charter) 3020 Callan Road San Diego, California 92121 (858) 401-7900 (Address, including zip code, and telephone number, including area code, of registra…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001599901 Avidity Biosciences, Inc. 001-39321 3020 Callan Rd., San Diego CA CALIFORNIA 92121 858-401-7900 Common Stock 17 CFR 240.12d2-2(a)(2) Tara Petta Director 2026-02-27
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The disclosures under the Introductory Note are incorporated herein by reference. On February 27, 2026, the Company (i) notified the Nasdaq Global Select Market ( Nasdaq ) of the consummation of the Merger and its intent to remove all Company Common Stock from Nasdaq and (ii) requested that Nasdaq (A) maintain the halt on trading of Company Common Stock, which was effective at 8:00 p.m. East…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:32 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:14 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:14 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.